Effects of Toll-like receptor antagonist 4,5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet

다국어 초록 (Multilingual Abstract)

Background: Obesity-related metabolic disorders are closely associated with inflammation induced by innate immunity. Toll-like receptors (TLRs) play a pivotal role in the innate immune system by activating proinflammatory signaling pathways. GIT27 (4,5-dihydro-3-phenyl-5-isoxasole acetic acid) is an active immunomodulatory agent that primarily targets macrophages and inhibits secretion of tumor necrosis factor α [as well as interleukin (IL)-1β, IL-10, and interferon γ]. However, the effect of TLR antagonist on kidney diseases has rarely been reported. We investigated whether the TLR antagonist GIT27 has beneficial effects on the progression of kidney disease in obese mice on a high-fat diet (HFD).
Methods: Six-week-old male C57BL/6 mice were divided into three groups: mice fed with normal chow diet (N=4); mice fed with a HFD (60% of total calories from fat, 5.5% from soybean oil, and 54.5% from lard, N=4); and GIT27-treated mice fed with a HFD (N=7).
Results: Glucose intolerance, oxidative stress, and lipid abnormalities in HFD mice were improved by GIT27 treatment. In addition, GIT27 treatment decreased the urinary excretion of albumin and protein in obesity-related kidney disease, urinary oxidative stress markers, and inflammatory cytokine levels. This treatment inhibited the expression of proinflammatory cytokines in the kidneys and adipose tissue, and improved extracellular matrix expansion and tubulointerstitial fibrosis in obesity-related kidney disease.
Conclusion: TLR inhibition by administering GIT27 improved metabolic parameters. GIT27 ameliorates abnormalities of lipid metabolism and may have renoprotective effects on obesity-related kidney disease through its anti-inflammatory properties.

참고문헌 (Reference)

1 Kang, Y. S., "chemokine receptor 2 antagonists in metabolic disease : a review of recent developments" 20 : 745-756, 2011

2 Zuany-Amorim, C., "Toll-like receptors as potential therapeutic targets for multiple diseases" 1 : 797-807, 2002

3 Brown, H. J., "Toll-like receptor 4 ligation on intrinsic renal cells contributes to the induction of antibody-mediated glomerulonephritis via CXCL1 and CXCL2" 18 : 1732-1739, 2007

4 Lin, M., "The TLR4 antagonist CRX-526 protects against advanced diabetic nephropathy" 83 : 887-900, 2013

5 Nagai, Y., "The TLR family protein RP105/MD-1 complex : a new player in obesity and adipose tissue inflammation" 2 : 61-66, 2013

6 Liu, B., "TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease" 177 : 6880-6888, 2006

7 Shi, H., "TLR4 links innate immunity and fatty acid-induced insulin resistance" 116 : 3015-3025, 2006

8 Wu, H., "TLR4 activation mediates kidney ischemia/reperfusion injury" 117 : 2847-2859, 2007

9 Takeda, K., "TLR signaling pathways" 16 : 3-9, 2004

10 Amann, K., "Structural renal changes in obesity and diabetes" 33 : 23-33, 2013

11 Kang, S. C., "Sphingolipid metabolism and obesity-induced inflammation" Frontiers in Endocrinology 4 : 1-11, 2013

12 Lee, J. Y., "Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4" 276 : 16683-16689, 2001

13 Cunningham, P. N., "Role of Toll-like receptor 4 in endotoxin-induced acute renal failure" 172 : 2629-2635, 2004

14 Cha, J. J., "Renal Protective Effects of Toll-like Receptor 4 Signaling Blockade in Type 2 Diabetic Mice" ENDOCRINE SOC 154 (154): 2144-2155, 2013

15 Sieber, J., "Regulation of podocyte survival and endoplasmic reticulum stress by fatty acids" 299 : F821-F829, 2010

16 Majdalawieh, A., "Regulation of IκBα function and NF-κB signaling : AEBP1 is a novel proinflammatory mediator in macrophages" 823821 : 1-27, 2010

17 Weisberg, S. P., "Obesity is associated with macrophage accumulation in adipose tissue" 112 : 1796-1808, 2003

18 Wickman, C., "Obesity and kidney disease : potential mechanisms" 33 : 14-22, 2013

19 Cignarelli, M., "Obesity and kidney disease" 17 : 757-762, 2007

20 Fasshauer, M., "Isoproterenol inhibits resistin gene expression through a G(S)-protein-coupled pathway in 3T3-L1 adipocytes" 500 : 60-63, 2001

21 Schaffler, A., "Innate immunity and adipose tissue biology" 31 : 228-235, 2010

22 Stojanovic, I., "In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027 : Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models" 123 : 311-323, 2007

23 Mangano, K., "In vitro inhibition of enterobacteria-reactive CD4+CD25-T cells and suppression of immunoinflammatory colitis in mice by the novel immunomodulatory agent VGX-1027" 586 : 313-321, 2008

24 Han, S. Y., "High glucose and angiotensin ll increase beta1 integrin and integrin-linked kinase synthesis in cultured mouse podocytes" 323 : 321-332, 2006

25 Dasu, M.R., "Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors" 300 : E145-E154, 2011

26 Tripathy, D., "Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects" 52 : 2882-2887, 2003

27 Goldstein, D. R., "Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection" 111 : 1571-1578, 2003

28 Young, B. A., "Cellular events in the evolution of experimental diabetic nephropathy" 47 : 935-944, 1995

29 Lee, M. H., "Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue" NATURE PUBLISHING GROUP 74 (74): 890-900, 2008

30 Kwon, H., "Adipokines mediate inflammation and insulin resistance" 4 : 1-13, 2013

31 Lago, F., "Adipokines as emerging mediators of immune response and inflammation" 3 : 716-724, 2007

32 Guzik, T. J., "Adipocytokines—novel link between inflammation and vascular function?" 57 : 505-528, 2006

33 Bligh, E. G., "A rapid method of total lipid extraction and purification" 37 : 911-917, 1959

34 Stosic-Grujicic, S., "A potent immunomodulatory compound, (S, R)-3-phenyl-4, 5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in nod mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice" 320 : 1038-1049, 2007